Sei Investments Co. raised its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 18.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 120,313 shares of the medical research company’s stock after buying an additional 18,921 shares during the period. Sei Investments Co.’s holdings in PerkinElmer were worth $8,198,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. ING Groep NV boosted its stake in shares of PerkinElmer by 0.6% in the second quarter. ING Groep NV now owns 6,057 shares of the medical research company’s stock valued at $413,000 after buying an additional 38 shares during the last quarter. CIBC Asset Management Inc boosted its stake in shares of PerkinElmer by 0.4% in the second quarter. CIBC Asset Management Inc now owns 9,549 shares of the medical research company’s stock valued at $651,000 after buying an additional 40 shares during the last quarter. LS Investment Advisors LLC boosted its stake in shares of PerkinElmer by 2.1% in the second quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock valued at $196,000 after buying an additional 60 shares during the last quarter. Tributary Capital Management LLC boosted its stake in shares of PerkinElmer by 0.3% in the second quarter. Tributary Capital Management LLC now owns 22,300 shares of the medical research company’s stock valued at $1,520,000 after buying an additional 75 shares during the last quarter. Finally, Meeder Asset Management Inc. boosted its stake in shares of PerkinElmer by 0.6% in the second quarter. Meeder Asset Management Inc. now owns 14,777 shares of the medical research company’s stock valued at $1,007,000 after buying an additional 83 shares during the last quarter. Institutional investors and hedge funds own 92.77% of the company’s stock.

PerkinElmer, Inc. (NYSE PKI) opened at 63.93 on Friday. The firm’s 50-day moving average price is $67.37 and its 200-day moving average price is $60.75. PerkinElmer, Inc. has a 1-year low of $45.35 and a 1-year high of $70.16. The firm has a market cap of $7.05 billion, a price-to-earnings ratio of 19.28 and a beta of 0.75.

PerkinElmer (NYSE:PKI) last released its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $547 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. PerkinElmer’s revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 earnings per share. On average, equities research analysts anticipate that PerkinElmer, Inc. will post $2.89 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, November 10th. Shareholders of record on Friday, October 20th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.44%. The ex-dividend date is Thursday, October 19th. PerkinElmer’s payout ratio is 8.46%.

ILLEGAL ACTIVITY WARNING: “PerkinElmer, Inc. (NYSE:PKI) Position Raised by Sei Investments Co.” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.watchlistnews.com/perkinelmer-inc-nysepki-position-raised-by-sei-investments-co/1480794.html.

PKI has been the subject of several research reports. Cantor Fitzgerald cut PerkinElmer from an “overweight” rating to a “neutral” rating and set a $60.00 price target for the company. in a research report on Wednesday, April 19th. Zacks Investment Research upgraded PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price target for the company in a research report on Wednesday, July 19th. Morgan Stanley reiterated an “overweight” rating and set a $79.00 price target (up from $73.00) on shares of PerkinElmer in a research report on Monday, July 10th. Evercore ISI reiterated an “in-line” rating and set a $68.00 price target (up from $62.50) on shares of PerkinElmer in a research report on Thursday, June 22nd. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $49.00 price target on shares of PerkinElmer in a research report on Friday, May 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. PerkinElmer currently has a consensus rating of “Hold” and a consensus price target of $67.00.

In other PerkinElmer news, insider Andrew Okun sold 4,358 shares of the firm’s stock in a transaction on Monday, June 19th. The stock was sold at an average price of $65.00, for a total transaction of $283,270.00. Following the completion of the transaction, the insider now owns 16,799 shares of the company’s stock, valued at $1,091,935. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Peter Barrett sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $63.22, for a total value of $632,200.00. Following the transaction, the director now directly owns 29,200 shares of the company’s stock, valued at approximately $1,846,024. The disclosure for this sale can be found here. Insiders have sold 20,986 shares of company stock valued at $1,330,317 in the last three months. 2.20% of the stock is currently owned by company insiders.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.